Viva Biotech sells 24% stake in CRO business Viva Shanghai for $150m
Viva Biotech Holdings Group has announced the fundraising of nearly $150 million by transferring about 24% of its equity interest in Viva Shanghai, its chief entity for contract research organization (CRO) business, to Temasek, HighLight Capital (HLC), and True Light. The transaction has additionally resulted in a profit of around $60 million for the publicly […]